We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

DIASORIN MOLECULAR

DiaSorin Molecular LLC manufactures and distributes innovative molecular diagnostic products on the versatile LIAISON... read more Featured Products: More products

Download Mobile App




Molecular Diagnostics System Provides Lab-Quality Results at POC

By LabMedica International staff writers
Posted on 10 Jul 2025

Currently, there is a need for a comprehensive molecular diagnostics ecosystem that enables effective diagnostic stewardship, providing the diagnostic tools to offer the right tests, for the right patient, at the right time, ultimately leading to more accurate diagnoses, better patient outcomes, and more efficient use of healthcare resources. More...

Now, a point-of-care molecular diagnostics system aims to address the challenges faced by healthcare systems by empowering clinicians with rapid, reliable results that support a test-and-treat approach, enabling timely, informed decisions.

DiaSorin SpA (Saluggia, Italy) has submitted a 510(k) premarket notification and CLIA waiver application to the U.S. Food and Drug Administration (FDA) for its LIAISON NES, a next-generation molecular POC testing platform. The submission covers the LIAISON NES FLU A/B, RSV & COVID-19 panel, designed to simultaneously detect and differentiate four of the most common and clinically significant respiratory pathogens: influenza A, influenza B, SARS-CoV-2, and respiratory syncytial virus (RSV).

The LIAISON NES system is designed to provide laboratory-quality molecular results, delivering high diagnostic accuracy with the speed and simplicity needed at the POC. Its compact footprint, intuitive workflow, and connectivity features make it ideally suited for decentralized settings such as urgent care centers, emergency departments, and physician offices.

The LIAISON NES system minimizes operational, administrative, and supply chain concerns that historically have prevented adoption of POC diagnostics at many near-patient locations. The system aims to overcome these barriers by creating a solution that is rapid and easy to perform, alleviates supply chain constraints by providing a long shelf life at room temperature with automatic reordering for an uninterrupted supply of tests. 

In addition to the LIAISON NES system, the company's molecular offering ranges from targeted solutions on the LIAISON MDX, featuring several De Novo FDA-authorized specialty assays, to multiplex capabilities on the LIAISON PLEX, the first fully customizable syndromic molecular platform on the market, and the MAGPIX platform for high-throughput syndromic testing. This integrated portfolio supports a broad spectrum of diagnostic needs, from centralized lab testing to rapid, near-patient diagnostics.

"The future of diagnostic testing lies in addressing real world challenges," said Carlo Rosa, CEO of Diasorin. "As leaders in diagnostics, we remain steadfast in our commitment to innovation, delivering solutions that empower healthcare systems to maintain and elevate patient care, even amid cost pressures and resource constraints. The LIAISON NES submission to the FDA aligns with the strategic priorities outlined at our 2023 Investor Day and marks another significant milestone in our path to enter the near-patient molecular diagnostics space, matching emerging medical needs."

Related Links:
DiaSorin SpA


New
Gold Member
Serological Pipets
INTEGRA Serological Pipets
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Rapid Test Reader
DIA5000
New
Human Estradiol Assay
Human Estradiol CLIA Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: The microfluidic device for passive separation of platelet-rich plasma from whole blood (Photo courtesy of University of the Basque Country)

Portable and Disposable Device Obtains Platelet-Rich Plasma Without Complex Equipment

Platelet-rich plasma (PRP) plays a crucial role in regenerative medicine due to its ability to accelerate healing and repair tissue. However, obtaining PRP traditionally requires expensive centrifugation... Read more

Immunology

view channel
Image: PD-1 protein blockade is the standard treatment for advanced melanoma among the different types of immunotherapy (Photo courtesy of 123RF)

Precision Tool Predicts Immunotherapy Treatment Failure in Melanoma Patients

Melanoma, though accounting for only about 4% of skin tumors, is the deadliest form of skin cancer due to its high potential to metastasize. While immunotherapy, especially PD-1 protein blockade, has revolutionized... Read more

Pathology

view channel
Image: Researchers have developed a novel method to analyze tumor growth rates (Photo courtesy of Adobe Stock)

Novel Method To Analyze Tumor Growth Rates Helps Tracks Progression Between Diagnosis and Surgery

Patients diagnosed with breast cancer often worry about how quickly their tumors grow while they wait for surgery, and whether delays in treatment might allow the disease to spread beyond the point of cure.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.